Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says
Executive Summary
Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.
You may also be interested in...
Wegovy Buoys Novo Nordisk To Highest-Ever Sales
But the Danish group is still bedeviled by supply problems, and much is hanging on upcoming cardiovascular outcomes data.
Lilly Expects Mounjaro To Benefit From Novo Nordisk Cardiovascular Trial
An exec said results from the SELECT trial of Wegovy could benefit the GLP-1 agonist class, given that employers tend to opt into drug classes when covering obesity treatments.
Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.